Mesalazine Aurobindo (Mesalazine)

Mesalazine inhibits the cyclooxygenase and lipoxygenase pathways in the colonic mucosa, leading to decreased production of prostaglandins and leukotrienes. This local anti‑inflammatory action reduces immune cell activation and cytokine release, helping to control inflammation associated with inflammatory bowel disease.

The specific dose and dosing schedule of Mesalazine Aurobindo are determined by the prescribing clinician based on the patient’s disease severity, location, and response to therapy. Healthcare professionals tailor the regimen to each individual’s clinical needs.

Safety data for mesalazine in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the Mesalazine Aurobindo product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Mesalazine belongs to the aminosalicylate class, offering a topical anti‑inflammatory effect directly in the colon. Compared with systemic immunosuppressants or biologics, it generally has a more favorable safety profile but may be less potent for severe disease. Choice of therapy depends on disease severity, location, and patient-specific factors.

Mesalazine Aurobindo should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency.

The product is supplied as a rectal formulation, typically in the form of suppositories or enemas. Administration is performed by inserting the dose into the rectum according to the prescriber’s instructions, usually after bowel evacuation and before bedtime for optimal contact time.

Serious adverse events include severe allergic reactions (e.g., anaphylaxis), hepatotoxicity, blood dyscrasias such as neutropenia or thrombocytopenia, pancreatitis, and interstitial nephritis. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Mesalazine Aurobindo is contraindicated in individuals with known hypersensitivity to mesalazine, salicylates, or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored, and in those with acute fulminant ulcerative colitis where systemic therapy is required.